Literature DB >> 9111136

A two-site lectinoenzymatic assay for determination of tumour marker glycoproteins in rectal secretions.

T F Orntoft1, J Jepsen, P V Hansen, U Raundahl, N C Langkilde.   

Abstract

A method is described for a titre-tray based two-site lectinoenzymatic assay of glycoproteins. WGA lectin, reacting with the core-part of glycans, was combined with lectins PNA and DBA, the latter two reacting with terminal parts of glycans. A standard curve was obtained with bovine submaxillary gland asialomucin, and measurements of human rectal secretion were calibrated against this curve. The assay showed an intra-assay reproducibility of 2.4-7.5%, and inter-assay reproducibility of 3.9-20.8%. Recovery tests showed a linearity close to predicted values. The selected standard was ideal as inhibition of lectin binding by monosaccharides showed similar inhibition profiles for human rectal secretion and for asialomucin standard. Neuraminidase treatment dramatically increased the PNA binding to human rectal secretion immobilized on WGA. Western blotting of human rectal secretion demonstrated a large range of lectin-reactive glycoproteins, the main fraction reacting with all lectins being approximately 250 kDa. The assay described is well suited for studies of the glycan part of tumour marker glycoproteins, and changes occurring in these. It has a high sensitivity by ignoring that the glycans may be present on different molecules. Examination of rectal secretions from various cancer patients showed significantly increased PNA binding, as well as an increased PNA/DBA binding ratio, in patients with colorectal cancer (p<3x10(-3)) and, unexpectedly, in patients with other cancers (p<5x10(-3)).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9111136     DOI: 10.1023/a:1018537720911

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  27 in total

Review 1.  Cytokines and the liver in health and disease. Effects on liver metabolism and fibrogenesis.

Authors:  T Andus; A Holstege
Journal:  Acta Gastroenterol Belg       Date:  1994 May-Aug       Impact factor: 1.316

Review 2.  Robert Feulgen Lecture 1993. L-selectin and its biological ligands.

Authors:  S D Rosen
Journal:  Histochemistry       Date:  1993-09

3.  Tumor-related elevation of serum (alpha 1----3)-L-fucosyltransferase activity in gastric cancer.

Authors:  S Yazawa; T Asao; Y Nagamachi; S A Abbas; K L Matta
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

4.  Carbohydrate structures of bovine submaxillary mucin.

Authors:  T Tsuji; T Osawa
Journal:  Carbohydr Res       Date:  1986-08-15       Impact factor: 2.104

Review 5.  Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens.

Authors:  S Hakomori
Journal:  Adv Cancer Res       Date:  1989       Impact factor: 6.242

6.  The effect of distant malignancy upon quantitative cytologic assessment of normal oral mucosa.

Authors:  G R Ogden; J G Cowpe; M W Green
Journal:  Cancer       Date:  1990-02-01       Impact factor: 6.860

7.  Adapting homogeneous enzyme-linked competitive binding assays to microtiter plates.

Authors:  B Kim; J M Buckwalter; M E Meyerhoff
Journal:  Anal Biochem       Date:  1994-04       Impact factor: 3.365

8.  O-linked mucin-type glycoproteins in normal and malignant colon mucosa: lack of T-antigen expression and accumulation of Tn and sialosyl-Tn antigens in carcinomas.

Authors:  T F Orntoft; N Harving; N C Langkilde
Journal:  Int J Cancer       Date:  1990-04-15       Impact factor: 7.396

9.  Ca 125 and Ca 19-9: two cancer-associated sialylsaccharide antigens on a mucus glycoprotein from human milk.

Authors:  F G Hanisch; G Uhlenbruck; C Dienst; M Stottrop; E Hippauf
Journal:  Eur J Biochem       Date:  1985-06-03

10.  Glycoconjugate with Ulex europaeus agglutinin-I-binding sites in normal mucosa, adenoma, and carcinoma of the human large bowel.

Authors:  S Yonezawa; T Nakamura; S Tanaka; E Sato
Journal:  J Natl Cancer Inst       Date:  1982-10       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.